Cargando…
Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
Background: The management of cholangiocarcinoma is continually reviewed on a current evidence basis to develop practice guidelines and consensus statements. However, the standardized treatment guidelines are still unclear for cholangiocarcinoma patients who are listed for liver transplantation. We...
Autores principales: | Abdelrahim, Maen, Al-Rawi, Hadeel, Esmail, Abdullah, Xu, Jiaqiong, Umoru, Godsfavour, Ibnshamsah, Fahad, Abudayyeh, Ala, Victor, David, Saharia, Ashish, McMillan, Robert, Al Najjar, Ebtesam, Bugazia, Doaa, Al-Rawi, Maryam, Ghobrial, Rafik M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139862/ https://www.ncbi.nlm.nih.gov/pubmed/35621680 http://dx.doi.org/10.3390/curroncol29050290 |
Ejemplares similares
-
Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022) -
Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
por: Abdelrahim, Maen, et al.
Publicado: (2022) -
Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
por: Abdelrahim, Maen, et al.
Publicado: (2022) -
Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
por: Badheeb, Mohamed, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
por: Abboud, Karen, et al.
Publicado: (2023)